XTalks

AUGUST 8, 2022

The company has developed a proprietary discovery platform called I-ReSToRE ( RE ceptor S election and T argeting t o R einstate immune E quilibrium) that has the potential to support the development of agonist antibodies targeting immune inhibitory receptors to treat inflammatory diseases. PD-1 is a potent immune inhibitory receptor.

Immune Response 89

Immune Response Antibody Life Science Engineer 89

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Cell-Based Immunotherapy vs. Immune Biologics. protein-based biologics) and vaccine treatments.

Protein 81

Protein Engineer Immune Response In-Vivo 81

Cloudbyz

MARCH 6, 2024

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. Personalized Medicine: Biologics offer the potential for personalized treatment approaches by taking into account individual variations in genetics, immune responses, and disease characteristics.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

pharmaphorum

NOVEMBER 23, 2021

The French drugmaker has been enticed by an artificial intelligence (AI) algorithm developed by Chinese tech giant Baidu, which controls most of China’s search engine traffic and is sometimes referred to as the country’s Google. Specific financial terms have not been disclosed.

Licensing 105

Licensing Licensing Vaccination Vaccine 105

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

Cloudbyz

MARCH 5, 2024

Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells. Mode of Action : Small Molecules: They often work by binding to specific sites on target proteins to inhibit or activate their function, which can affect various biological pathways inside the cell.

Development 97

Development Drugs Manufacturing Immune Response 97

pharmaphorum

APRIL 8, 2022

It was shown to activate cell-killing immune responses via natural killer (NK) and CD8+ cells, as well as antigen-presenting cells. The deal is also a first partnership focusing on Werewolf’s PREDATOR protein engineering platform, which also includes IL-2 (WTX-124) and IL-12 (WTX-330) candidates preclinical development.

Drugs 105

Drugs Immune Response Licensing Licensing 105

pharmaphorum

AUGUST 23, 2021

DNA vaccines work by delivering a genetically-engineered plasmid containing the DNA sequence encoding the desired antigen – in this case the SARS-CoV-2 spike protein – which is then taken up by cells. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

The Pharma Data

NOVEMBER 22, 2020

Pandion focuses on the development of innovative modular therapeutics using its TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform. The TALON effector modules are based on immunomodulatory molecules that act as regulatory control points within the immune system.

Antibody 52

Antibody Engineer Immune Response Protein 52

The Pharma Data

APRIL 22, 2023

These “acute inflammatory lesions” then attract other myeloid cells, as well as self-reactive T and B cells that belong to the immune system’s second arm, known as the “adaptive immune system” and directly attack the myelin covering. “Current MS therapies do not specifically target myeloid cells. .

Immune Response 40

Immune Response Engineer In-Vivo Containment 40

XTalks

SEPTEMBER 21, 2023

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. These T cells are engineered to recognize various HIV proteins in a unique manner compared to previous experimental HIV vaccines. Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

pharmaphorum

MARCH 10, 2021

The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 1 mutations, as well as variants from the UK and South Africa. That work in the Manaus area, where the variant first emerged, has estimated that P.1

Vaccination 66

Vaccination Vaccine Genetic Engineering Engineer 66

The Pharma Data

SEPTEMBER 30, 2021

Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccination 52

Vaccination Vaccine Immune Response Licensing 52

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. Patients have better quality of life thanks to many Grifols plasma-derived medicines that replace missing or deficient plasma proteins.

Medicine 104

Medicine Recombinant Antibody Protein Antibody 104

The Pharma Data

NOVEMBER 9, 2020

Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 1, 2022

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Previous research has shown that caspase 11 in mice has many of the same immune-response functions as caspase 4 in humans.

Immune Response 52

Immune Response Genetic Engineering Research Engineer 52

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. Developed by Gilead, Sunlenca is the first drug in a novel class known as capsid inhibitors to receive FDA approval for treating HIV-1. In November 2023, Hookipa Pharma Inc.,

FDA Approval 108

FDA Approval Gene Therapy Clinical Trials Gene 108

The Pharma Data

JANUARY 22, 2021

iosBio has claimed the OraPro platform enables oral delivery of thermally-stable, viral vector vaccines, which are engineered to withstand temperatures of up to 50°C. When multiple mutations occur at the receptor-binding domain of the spike protein, it renders antibodies ineffective.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

The Pharma Data

NOVEMBER 30, 2020

CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix?M. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. The award is funding the U.S.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

XTalks

MAY 24, 2024

” XTALKS WEBINAR: AI-based Antibody Therapeutics Developability Assessment and Its Engineering Live and On-Demand: Friday, June 21, 2024, at 10am EDT (4pm CEST/EU-Central) Register for this webinar today to learn how AI can be used to improve developability screening of antibody therapeutics and optimization of antibody candidates.

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

The Pharma Data

AUGUST 9, 2021

Dr Munir said: “Our studies demonstrate that induction of a local immune response at the point of entry of SARS-CoV-2 has the potential to not only limit clinical disease, but also – and perhaps even more importantly – virus transmission from infected to uninfected individuals.”

Vaccination 52

Vaccination Vaccine Immune Response Scientist 52

pharmaphorum

FEBRUARY 25, 2021

The first trial showed that it could increase levels of Treg cells thought to be involved in dampening down immune responses.

Clinical Trials 71

Clinical Trials Clinical Trials Immune Response Trials 71

XTalks

NOVEMBER 23, 2020

Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials. The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions.

Vaccination 79

Vaccination Vaccine Clinical Trials Clinical Trials 79

The Pharma Data

JANUARY 17, 2021

Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days. The data showed that the vaccine induced an immune response and was generally well-tolerated.

Immune Response 52

Immune Response Antibody Trials Clinical Trials 52

The Pharma Data

JANUARY 11, 2021

Using its novel yeast display system and large diverse human antibody libraries, AvantGen has identified a panel of high affinity human monoclonal antibody clones that bind to two distinct epitopes on the receptor binding domain of the SARS-CoV-2 spike protein.

Antibody 52

Antibody Licensing Licensing Development 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. The BET inhibitor worked by increasing beta-3 tubulin (TUBB3), a protein found in brain metastases. Brown fat generates heat in response to low temperatures due to its expression of the protein UCP1.

Vaccination 53

Vaccination Vaccine Research Trials 53

pharmaphorum

NOVEMBER 2, 2021

The more targeted, bispecific functionality of bsAbs broadens the reach of antibody-mediated therapies against both solid and haematological cancers, creating novel approaches that can induce a tumour-specific immune response, target immune checkpoints, or improve payload delivery to tumour cells (Fig.

Antibody 52

Antibody Immune Response Production Engineer 52

Roots Analysis

MAY 21, 2024

LNPs comprise of a lipid bilayer that surrounds a hydrophobic core, which can be loaded with therapeutic agents ( such as drugs, genetic material and proteins ). LNPs can also be engineered to encapsulate multiple antigens, enabling the development of multivalent vaccines.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Roots Analysis

OCTOBER 30, 2023

These RNA based therapeutics play a crucial role in protein production and regulation of gene functions. Self-amplifying RNA (saRNA): Self amplifying RNA is an engineered form of RNA, combining the amplifying genome (native to certain viruses) to the therapeutic gene of interest.

RNA 40

RNA Vaccination Vaccine Development 40

pharmaphorum

NOVEMBER 29, 2022

T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. NT-I7 (efineptakin alfa). NeoImmuneTech is betting on what has proved to be the most efficient natural weapon against cancer: T cells. He received his Ph.D.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Engineer 105

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

The Pharma Data

AUGUST 22, 2021

This is how many medical studies begin, said biomedical engineering professor Phil Bourne, who serves as founding dean for the School of Data Science. One of the most dangerous phenomena COVID-19 can trigger in your body is something called a cytokine storm, which is a potentially fatal amplification of an immune response.

Doctors 52

Doctors Doctor Drugs Scientist 52

The Pharma Data

OCTOBER 27, 2020

B cells are prolific protein producers that can be collected from peripheral blood, have a programmable lifetime that could last decades, can target specific tissues, and have customizable functionality. Be Bio plans to use their $52 million Series A to precisely engineer B cells to treat a range of diseases. The company’s $27.4

Gene 52

Gene Gene Therapy Medicine Development 52

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.

Vaccination 40

Vaccination Vaccine Development Medicine 40

pharmaphorum

MARCH 3, 2021

Novavax’s vaccine is a sequence of protein engineered from the genetic sequence of the SARS-CoV-2 virus that mimics the “Spike” protein found on the pathogen’s surface. It cannot replicate or cause the disease but does produce a strong immune response that neutralises the virus in the event of an infection.

Vaccination 130

Vaccination Vaccine Regulation Immune Response 130